Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic umbilical cord-derived mesenchymal stem cell implantation for critical limb ischemia
2018-004563-31Phase 2Active
- Sponsor
- CHU de Reims
- Start
- Feb 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HB-MSC1 in chronic limb-threatening ischemia (CLTI), sponsored by CHU de Reims. Primary endpoint: Safety and tolerance. Started Feb 2019; status: active.
02
Drugs
HB-MSC1
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2018-004563-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004563-31.